Literature DB >> 7012176

Protease production by clinical isolates of type III group B streptococci.

D C Straus, S J Mattingly, T W Milligan, T I Doran, T J Nealon.   

Abstract

Six strains of serotype III group B streptococci isolated from confirmed cases of neonatal disease were examined for their ability to produce proteolytic enzymes. Three neuraminidase-producing strains and three non-neuraminidase-producing strains were employed in this study. Protease production was examined in 1,000-fold concentrated filtrates of stationary-phase cells with an insoluble substrate derived from horse hide powder labeled covalently with Remazol brilliant blue. Protease activity was not detected in any cultural supernatant fluids until they were fractionated on Sephadex G-100. After fractionation, the neuraminidase-producing strains were shown to elaborate approximately sixfold more protease than the non-neuraminidase-producing strains. The finding that clinical isolates of group B streptococci that elaborated high levels of neuraminidase also produced elevated levels of extracellular protease may indicate that the production of several different factors may determine the virulence of these organisms.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7012176      PMCID: PMC273600          DOI: 10.1128/jcm.12.3.421-423.1980

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  22 in total

1.  Caseinolytic and glyoprotein hydrolase activity of Streptococcus mutans.

Authors:  R A Cowman; M M Perrella; R J Fitzgerald
Journal:  J Dent Res       Date:  1976 May-Jun       Impact factor: 6.116

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Growth of several cariogenic strains of oral streptococci in a chemically defined medium.

Authors:  B Terleckyj; N P Willett; G D Shockman
Journal:  Infect Immun       Date:  1975-04       Impact factor: 3.441

Review 4.  Group B streptococci in human disease.

Authors:  M J Patterson; A El Batool Hafeez
Journal:  Bacteriol Rev       Date:  1976-09

5.  Assessment of protease (elastase) as a Pseudomonas aeruginosa virulence factor in experimental mouse burn infection.

Authors:  O R Pavlovskis; B Wretlind
Journal:  Infect Immun       Date:  1979-04       Impact factor: 3.441

6.  Experimental endocarditis in rabbits. 3. Significance of the proteolytic capacity of the infecting strains of Streptococcus faecalis.

Authors:  E Gutschik; S Møller; N Christensen
Journal:  Acta Pathol Microbiol Scand B       Date:  1979-12

7.  Nature and mechanism of action of the CAMP protein of group B streptococci.

Authors:  A W Bernheimer; R Linder; L S Avigad
Journal:  Infect Immun       Date:  1979-03       Impact factor: 3.441

8.  Distribution and serological specificity of sialidase produced by various groups of streptococci.

Authors:  S Hayano; A Tanaka; Y Okuyama
Journal:  J Bacteriol       Date:  1969-10       Impact factor: 3.490

9.  Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: extracellular protease and elastase as in vivo virulence factors.

Authors:  I A Holder; C G Haidaris
Journal:  Can J Microbiol       Date:  1979-05       Impact factor: 2.419

10.  A PROTEOLYTIC ENZYME PRODUCED BY GROUP A STREPTOCOCCI WITH SPECIAL REFERENCE TO ITS EFFECT ON THE TYPE-SPECIFIC M ANTIGEN.

Authors:  S D Elliott
Journal:  J Exp Med       Date:  1945-06-01       Impact factor: 14.307

View more
  11 in total

1.  Factors influencing release of type III antigens by group B streptococci.

Authors:  T I Doran; D C Straus; S J Mattingly
Journal:  Infect Immun       Date:  1981-02       Impact factor: 3.441

2.  Association of type- and group-specific antigens with the cell wall of serotype III group B streptococcus.

Authors:  T I Doran; S J Mattingly
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

3.  Type-specific capsular antigen is associated with virulence in late-onset group B Streptococcal type III disease.

Authors:  M E Klegerman; K M Boyer; C K Papierniak; L Levine; S P Gotoff
Journal:  Infect Immun       Date:  1984-04       Impact factor: 3.441

4.  Characterization of neuraminidases produced by various serotypes of group B streptococci.

Authors:  J G Brown; D C Straus
Journal:  Infect Immun       Date:  1987-01       Impact factor: 3.441

5.  Identification of a high-virulence clone of type III Streptococcus agalactiae (group B Streptococcus) causing invasive neonatal disease.

Authors:  J M Musser; S J Mattingly; R Quentin; A Goudeau; R K Selander
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

6.  Role of proteinase in the formation of inhibitory levels of hematin by group A streptococcus cultures on blood-containing media.

Authors:  W L Hynes; J R Tagg
Journal:  J Clin Microbiol       Date:  1986-05       Impact factor: 5.948

7.  Teichoic acids of Streptococcus agalactiae: chemistry, cytotoxicity, and effect on bacterial adherence to human cells in tissue culture.

Authors:  J C Goldschmidt; C Panos
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

8.  Protease production by Streptococcus sanguis associated with subacute bacterial endocarditis.

Authors:  D C Straus
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

9.  Correlation between the production of extracellular substances by type III group B streptococcal strains and virulence in a mouse model.

Authors:  D L Durham; S J Mattingly; T I Doran; T W Milligan; D C Straus
Journal:  Infect Immun       Date:  1981-11       Impact factor: 3.441

10.  Lysis of erythrocytes by a hemolysin produced by a group B Streptococcus sp.

Authors:  B A Marchlewicz; J L Duncan
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.